Relmada Therapeutics (RLMD) Income from Continuing Operations (2012 - 2026)
Relmada Therapeutics (RLMD) posted quarterly Income from Continuing Operations of 56426288.0 for Q1 2026, down 216.54% year-over-year from 48417145.0 in Q1 2025, and down 182.54% quarter-over-quarter from 19971046.0 in Q4 2025.
Powered by 
Analysis
Relmada Therapeutics (RLMD) Income from Continuing Operations (2012 - 2026) Analysis & Trends
Relmada Therapeutics (RLMD) has reported Income from Continuing Operations for 15 consecutive years, with 56426288.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 216.54% year-over-year to 56426288.0; the TTM figure through Mar 2026 stood at 96377515.0 (down 24.78% YoY), while the FY2025 annual figure was 64619425.0, up 19.72% from the prior year.
- Income from Continuing Operations eased to 56426288.0 in Q1 2026 per RLMD's latest filing, from 19971046.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 9899848.0 in Q2 2025 and bottomed at 56426288.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 27708773.18 across 5 years, with a median of 24703820.0 in 2023.
- Annual changes were most pronounced in 2025 — Income from Continuing Operations surged 55.7% — and 2026, when it tumbled 216.54%.
- Relmada Therapeutics' Income from Continuing Operations stood at 39120418.0 in 2022, then surged by 34.58% to 25592276.0 in 2023, then climbed by 27.91% to 18448910.0 in 2024, then retreated by 8.25% to 19971046.0 in 2025, then slumped by 182.54% to 56426288.0 in 2026.
- Business Quant data shows RLMD's Income from Continuing Operations at 56426288.0 in Q1 2026, 19971046.0 in Q4 2025, and 10080333.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Relmada Therapeutics | 498.39 Mn | 498.39 Mn | - | -12.71 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -12.71 Mn |
| Mar 31, 2026 | -18.50 Mn |
| Dec 31, 2025 | -19.95 Mn |
| Sep 30, 2025 | -10.08 Mn |
| Jun 30, 2025 | -9.90 Mn |
| Mar 31, 2025 | -17.78 Mn |
| Dec 31, 2024 | -18.42 Mn |
| Sep 30, 2024 | -22.15 Mn |
| Jun 30, 2024 | -17.86 Mn |
| Mar 31, 2024 | -21.93 Mn |
| Dec 31, 2023 | -25.57 Mn |
| Sep 30, 2023 | -21.37 Mn |
| Jun 30, 2023 | -24.66 Mn |
| Mar 31, 2023 | -26.95 Mn |
| Dec 31, 2022 | -38.70 Mn |
| Sep 30, 2022 | -38.74 Mn |
| Jun 30, 2022 | -45.51 Mn |
| Mar 31, 2022 | -38.30 Mn |
| Dec 31, 2021 | -34.18 Mn |
| Sep 30, 2021 | -42.65 Mn |